Novel Hypertension Diagnosis Processes: A Review of Pharmacological Intervention & New Technologies in the Development of Hypertension Care
Main Article Content
A major source of trouble for cardiovascular complaints is hypertension. Around one-third of patients with hypertension are currently undiagnosed, and of those who are, about half do not use any antihypertensive medications. According to the World Health Organization (WHO), high blood pressure kills at least nine million people worldwide every year, either directly or indirectly. Many pharmacological guidelines for antihypertensive medications, along with their basic properties and modes of response are discussed. To be able to determine what kind of high blood pressure a certain pharmacological nobility using antihypertensive medicine are most appropriate for, the medium of movement is examined using a pharmacological technique. Moreover, pharmacological processes are used to characterize aspect concerns For a deeper understanding of their frequency & the circumstances where outpatient specifics are not recommended. Beta-blockers, diuretics, Angiotensin II receptor antagonists, RAAS inhibitors, & calcium channel blockers are the other five key pharmacological antihypertensive groups. In addition, it contains an analysis of how emerging technologies can facilitate the advanced hypertension identification and treatment, not just for the general public also however in specific demographic subgroups like older people, ladies who are expecting and those who have atrial fibrillation.
Suzanne1, Maria Czarina Acelajado2, George L. Bakris3, Dan R. Berlowitz4,5, Renata Cífková6, Anna F. Dominiczak7, Guido Grassi8,9, Jens Jordan10, Neil R. Poulter11, Anthony Rodgers12, and Paul K. Whelton13, HHS Public Access, Nat Rev Dis Primers; 4: 18014. doi:10.1038/nrdp.2018.14.
Boutouyrie P, Achouba A, Trunet P, Laurent S; explor Trialist Group Amlodipine valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010; 55:1314-1322
Frishman WH1, Alwar Shetty M. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinetics. 2002; 41:505-516.
Schiffrin EL. remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertension. 2004;17(12 Pt 1):1192-1200
Danchin N, Laurent S. Coronary artery disease: Are β-blockers truly helpful in patients with CAD? Nat Rev Cardiol. 2012; 10:11-12.
Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Barron A, Mant D. Comparison of acceptability of and preferences for different methods of measuring blood pressure in primary care. BMJ. 2002;325(7358):258–9.
Boutouyrie P, Lacolley P, Briet M, Reignault V, Stanton A, Laurent S, Mahmud A. Pharmacological modulation of arterial stiffness. Drugs 2011; 71:1689-1701.
Pratheek Sharma1, Harshit Beria1, Praveen Kumar Gupta1, Sumathra Manokaran1, A.H. Manjunatha Reddy1, Prevalence of hypertension and its associated risk factors, Journal of pharmaceutical science and research, 11(6), 2019, 2161-2167
Qiannan Gaoa, Li Xuc, *, Jun Caia, b**, New drug targets for hypertension: A literature review, BBA-Molecular Basis of Disease 1867 (2021) 166037
SAHBANATHUL MISSRIYA MA*, JOHNCEY JOHN, ASSESS THE PREVALENCE OF HYPERTENSION AND KNOWLEDGE REGARDING THE PREVENTION OF STROKE, Asian Journal of Pharmaceutical and Clinical Research, Vol 10, Issue 8, 2017, 177-180
Laxmi Narayan Goit1*, Shaning Yang2, Treatment of Hypertension: A Review, Scientific research publishing, 2019, 3, 101-123
Kotchen TA. Historical trends and milestones in hypertension research: a model of the process of translational research. Hypertension. 2011; 58:522-538.
Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004; 93:990-996.
Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996; 51:792-819
Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010; 376:1476-1484.
Welling PG. Pharmacokinetics of the thiazide diuretics. Biopharm Drug Dispos. 1986; 7:501-535.